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Fig 1. Patients with hematologic relapse and no signs of cGVHD
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Background: Impacts of conditioning intensity and total
body irradiation (TBI) on acute graft-versus-host disease
(aGVHD) still remains a matter of debate, because the se-
lection of reduced intensity (RIC) or myeloablative condi-
tioning (MAC) is generally determined based on patient/
donor characteristics such as age, HLA mismatch, and donor
types.
Methods: We analyzed 5471 recipients (>15 years old) with
AML,ALL,CML or MDS who received allogeneic HCT between
2006 and 2009, using JSHCT registry database. Conditioning
is classiﬁed as High TBI(>8Gy)-MAC, Low TBI-MAC, nonTBI-
MAC, Low TBI-RIC and nonTBI-RIC. The impact of the types of
conditioning on aGVHD and other outcomes were assessed.
Subgroup analyses were also performed according to donor
types: HLA-matched related (MRD, n¼1374), HLA-mis-
matched related (MMRD, n¼429), HLA matched unrelated
(MUD, n¼1508), HLA mismatched unrelated donor (MMUD,
n¼820), and cord blood (CBT, n¼1340).
Results: The High TBI-MAC group included younger age and
more acute lymphoblastic leukemia. The Low TBI-MAC and
-RIC groups included more CBT and HLA mismatched BMT/
PBSCT. There was a signiﬁcant difference in the incidence of
aGVHD2-4: 39% in High TBI-MAC, 41% in Low TBI-MAC, 31%
in nonTBI-MAC, 37% in Low TBI-RIC, and 32% in nonTBI-RIC,
respectively (P<0.001). In multivariate analysis, TBI-con-
taining conditionings were signiﬁcantly associated with an
increased risk of aGVHD2-4: HR was 1.34 in High TBI-MAC
(P<0.001),1.50 in Low TBI-MAC (P<0.01),1.23 in Low TBI-RIC
(P¼0.011), and 1.21 in nonTBI-RIC (P¼0.051) in comparison
with nonTBI-MAC. Subgroup analyses revealed that the
adverse impact of High TBI-MAC on aGVHD2-4 was observed
only in HLA-matched BMT/PBSCT and CBT (HR¼1.61 in MRD,
P<0.001; HR¼1.44 in MUD, P<0.01; HR¼1.76 in CBT,
P¼0.042), while it disappeared in HLA-mismatched BMT/
PBSCT (HR¼0.72 in MMRD, P¼0.72; HR¼1.16 in MMUD,
P¼0.35). Other conditionings had no signiﬁcant impact on
aGVHD2-4 in subgroup analyses. For non-relapse mortality, a
favorable impact of High TBI-MAC was observed in MMUD
(HR¼0.66 in High TBI-MAC, P¼0.027), while any adverse
impact of TBI-conditioning on relapse/NRM was not
observed in any donor types. Finally, the conditioning types
had no impact on overall survival (OS) in MRD, MUD, and
CBT. Conversely, favorable impacts of TBI-conditioning on OS
were observed in MMRD (High TBI-MAC, HR¼0.54, P<0.01;
Low TBI-RIC, HR¼0.48, P<0.01) and MMUD (High TBI-MAC,
HR¼0.72, P¼0.026; Low TBI-RIC, HR¼0.65, P¼0.015) in
comparison with nonTBI-MAC. However, the impact of Low
TBI-RIC was not different from that of nonTBI-RIC, when we
focused only on RIC.
Conclusion: The adverse impact of High TBI-MAC on
aGVHD2-4 incidence was observed only in HLA-matched
BMT/PBSCT and CBT, but not in mismatched BMT/PBSCT. In
mismatched HCT, High TBI-MAC rather had a favorable
impact on OS and should not be avoided as long as there is no
contraindication.Fig 2. Reversion of declining CD34+ speciﬁc donor chimerism in 2 patients
with extensive chronic GVHD429
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Introduction: Success of allogeneic hematopoietic stem cell
transplant (allo-HSCT) for patients with acute myeloid leu-
kemia (AML) and myelodysplastic syndromes (MDS) largely
depends on graft versus leukemia (GVL) effect. Although GVL
cannot be directly measured in the clinical setting, its
development is frequently associated with the development
of chronic graft versus host disease (cGVHD). Here we
describe the assay, which allows monitoring of both minimal
residual disease (MRD) and GVL in MDS and AML patients
after allo-HCT.
Methods: MRD was monitored in high risk patients with
CD34+ MDS and AML by monthly peripheral blood CD34+
speciﬁc donor chimerism (PB CD34+ DC) analysis starting at
day +30 following allo-HCT. To obtain PB CD34+ DC, CD34+
cells were positively selected by immunomagnetic isolation
from peripheral blood followed by ﬂuorescence-activated
cell sorting. Highly puriﬁed CD34+ cells (>95%) were sub-
sequently evaluated for percentage of donor DNA contribu-
tion by short tandem repeat analysis.
Results: Between September 2011 and July 2013 subjects
with MDS or AML were monitored monthly by PB CD34+ DC
analysis. A rapid and steady decline in CD34+ donor chime-
rism was detected in all study participants who developed
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development of extensive c GVHD coincided with rapid
reversion of declining PB CD34+ DC. Restoration of PB CD34+
DC after cGVHD was associated with development of potent
GVL effect because both patients have remained disease free
for 12 and 15 months, respectively (Fig2).
Conclusions: Declining PB CD34+ DC associates with higher
risk for relapsed disease after allo-HCT. MRD and GVL can be
monitored serially by a non-invasive PB CD34+ DC assay. GVL
associates with cGVHD in patients with MDS and AML.
Monitoring of PB CD34+ DC may identify at-risk patients
eligible for early withdrawal of immunosuppression or post-
transplant allograft modulation.Figure 2.430
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Introduction: The concentration of cyclosporine A (CsA)
after allogeneic stem cell transplantation has been reported
to be important in prevention of acute graft versus host
disease (aGVHD). The target concentration and method of
monitoring CsA concentration varies between transplant
centers. More knowledge is needed to tailor the intensity of
post transplant immunosuppression in relation to the risk of
aGVHD, disease relapse and nephrotoxicity.
Methods: We retrospectively analyzed data from 48 adult
patients, who consecutively underwent myeloablative allo-
geneic stem cell transplantation in the years 2010 and 2011
at Rigshospitalet, Copenhagen. Transplant indications were
AML (n¼18), ALL (n¼14), MDS (n¼3), SAA (n¼6), MM (n¼2)
and other (n¼5). Whole blood concentration of CsA was
measured once daily 8 hours after the administration of CsA.
The median CsA concentration in weeks 1 to 4 was calcu-
lated, and patients were divided into two equally sized
groups according to the median CsA concentration. Renal
impairment was deﬁned as doubling of serum creatinineFigure 1.during the ﬁrst 28 days after transplantation. Comparison of
groups with or without aGVHD grade II or more was done
using the chi square test for categorical variables. Variables
with a p<0.1 were further analyzed using multivariate lo-
gistic regression. Probability of developing aGVHD was
calculated using the cumulative incidence procedure with
death as competing event.
Results: Themedian concentrations of CsA in each of the ﬁrst
4 weeks after transplantation are shown in ﬁgure 1. The
proportion of patients with aGVHD grade II-IV was higher in
those with CsA levels below the median 2 weeks after
transplantation (p¼0.019). This association was also found
when assessing the cumulative incidence of aGVHD with
death as competing event (p¼0.012, ﬁgure 2), and further-
more remains signiﬁcant in multivariate analysis after
adjusting for donor relation, TBI and donor sex. All cases of
aGVHD (n¼20) occurred after 2 weeks from time of trans-
plantation. CsA levels at week 1, 3 and 4 did not affect the risk
of aGVHD. Importantly, CsA levels were not correlated with
excess risk of developing renal impairment. No relation was
found between CsA levels and death from relapse (P¼0.73).
Conclusion: This study indicates a close relationship be-
tween the concentration of CsA in the early post-transplant
period and development of aGVHD grade II or more. Neph-
rotoxicity was not an obstacle for achieving higher concen-
trations of CsA. Therefore, close monitoring of the CsA
concentration in the early transplant period is important in
maintaining CsA within target concentration and thus pre-
venting development of aGVHD. Target concentration of CsA
early in the post transplant course should possibly be
adjusted to higher levels than we observed in this series of
patients. Cumulative incidence of aGVHD (1) and death (2)
for groups with high and low CsA.431
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In an adult study, Nash et al. (Blood, 2000) recommended to
maintain tacrolimus levels between 10-20ng/ml for aGVHD
prophylaxis. The optimal range for tacrolimus levels in
